[Erythropoietin protects retinal ganglion cells and visual function after ocular ischemia and optic nerve compression]. 2010

T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
Augenklinik des Klinikums der Albert-Ludwigs-Universität Freiburg i.Br., Killianstrasse 5, 79106, Freiburg i.Br. tomjeh@googlemail.com

BACKGROUND The glycoprotein erythropoietin (EPO) has been shown to be protective in models of neuronal disease and reduced apoptosis of retinal ganglion cells (RGC) after transection of the optic nerve and in glaucoma. In this study we assessed in vivo the properties of EPO on survival of RGC after ischemia and optic nerve compression, as well as on postischemic visual function. Furthermore, the safety of intravitreal injection was assessed. METHODS In all experiments, EPO was administered intravitreally in male Brown Norway rats. Ocular ischemia was induced by elevating the intraocular pressure for 55 min. The calibrated optic nerve compression was performed for 10 s. RGC were marked stereotactically and quantified by fluorescence microscopy. The retinal function was quantified by electroretinography (ERG) and the whole visual pathway by visual evoked potential (VEP). RESULTS EPO (2 and 20 units per eye, n=9-21) increased the survival of RGC after ischemia by 21+/-21% and 127+/-31% (mean +/- SEM) and after optic nerve compression by 28+/-12% and 58+/-13%. With EPO (20 units), postischemic function was increased, in ERG by 71+/-13% (a-wave) and 75+/-19% (b-wave) and in VEP by 264+/-65% (p=0.053). Neither the ERG parameters, nor the VEP, nor the number of RGC differed significantly after intravitreal injection of EPO (5, 50, and 200 units, n=6-7) in healthy eyes. CONCLUSIONS The combination of toxicological safety and protection of retinal neurons makes EPO a promising drug for ischemic retinal diseases and traumatic optic neuropathy.

UI MeSH Term Description Entries
D008297 Male Males
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005074 Evoked Potentials, Visual The electric response evoked in the cerebral cortex by visual stimulation or stimulation of the visual pathways. Visual Evoked Response,Evoked Potential, Visual,Evoked Response, Visual,Evoked Responses, Visual,Potential, Visual Evoked,Potentials, Visual Evoked,Response, Visual Evoked,Responses, Visual Evoked,Visual Evoked Potential,Visual Evoked Potentials,Visual Evoked Responses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014786 Vision Disorders Visual impairments limiting one or more of the basic functions of the eye: visual acuity, dark adaptation, color vision, or peripheral vision. These may result from EYE DISEASES; OPTIC NERVE DISEASES; VISUAL PATHWAY diseases; OCCIPITAL LOBE diseases; OCULAR MOTILITY DISORDERS; and other conditions (From Newell, Ophthalmology: Principles and Concepts, 7th ed, p132). Hemeralopia,Macropsia,Micropsia,Day Blindness,Metamorphopsia,Vision Disability,Visual Disorders,Visual Impairment,Blindness, Day,Disabilities, Vision,Disability, Vision,Disorder, Visual,Disorders, Visual,Hemeralopias,Impairment, Visual,Impairments, Visual,Macropsias,Metamorphopsias,Micropsias,Vision Disabilities,Vision Disorder,Visual Disorder,Visual Impairments
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018917 Optic Neuropathy, Ischemic Ischemic injury to the OPTIC NERVE which usually affects the OPTIC DISK (optic neuropathy, anterior ischemic) and less frequently the retrobulbar portion of the nerve (optic neuropathy, posterior ischemic). The injury results from occlusion of arterial blood supply which may result from TEMPORAL ARTERITIS; ATHEROSCLEROSIS; COLLAGEN DISEASES; EMBOLISM; DIABETES MELLITUS; and other conditions. The disease primarily occurs in the sixth decade or later and presents with the sudden onset of painless and usually severe monocular visual loss. Anterior ischemic optic neuropathy also features optic disk edema with microhemorrhages. The optic disk appears normal in posterior ischemic optic neuropathy. (Glaser, Neuro-Ophthalmology, 2nd ed, p135) Anterior Ischemic Optic Neuropathy,Ischemic Optic Neuropathy,NAION,Nonarteritic Anterior Ischemic Optic Neuropathy,Optic Ischaemic Neuropathy,Optic Ischemic Neuropathy,Optic Nerve Ischemia,Posterior Ischemic Optic Neuropathy,Optic Neuropathy, Anterior Ischemic,Optic Neuropathy, Posterior Ischemic,Ischaemic Neuropathy, Optic,Ischemia, Optic Nerve,Ischemic Neuropathy, Optic,Ischemic Optic Neuropathies,Nerve Ischemia, Optic,Neuropathy, Ischemic Optic,Neuropathy, Optic Ischaemic,Neuropathy, Optic Ischemic,Optic Ischaemic Neuropathies,Optic Ischemic Neuropathies,Optic Nerve Ischemias
D020221 Optic Nerve Injuries Injuries to the optic nerve induced by a trauma to the face or head. These may occur with closed or penetrating injuries. Relatively minor compression of the superior aspect of orbit may also result in trauma to the optic nerve. Clinical manifestations may include visual loss, PAPILLEDEMA, and an afferent pupillary defect. Optic Nerve Trauma,Optic Neuropathy, Traumatic,Second Cranial Nerve Trauma,Cranial Nerve II Injuries,Optic Nerve Avulsion,Optic Nerve Contusion,Optic Nerve Transection,Second Cranial Nerve Injuries,Trauma, Second Cranial Nerve,Avulsion, Optic Nerve,Avulsions, Optic Nerve,Contusion, Optic Nerve,Contusions, Optic Nerve,Injuries, Optic Nerve,Injury, Optic Nerve,Nerve Avulsion, Optic,Nerve Avulsions, Optic,Nerve Contusion, Optic,Nerve Contusions, Optic,Nerve Injuries, Optic,Nerve Injury, Optic,Nerve Transection, Optic,Nerve Transections, Optic,Nerve Trauma, Optic,Nerve Traumas, Optic,Neuropathies, Traumatic Optic,Neuropathy, Traumatic Optic,Optic Nerve Avulsions,Optic Nerve Contusions,Optic Nerve Injury,Optic Nerve Transections,Optic Nerve Traumas,Optic Neuropathies, Traumatic,Transection, Optic Nerve,Transections, Optic Nerve,Trauma, Optic Nerve,Traumas, Optic Nerve,Traumatic Optic Neuropathies,Traumatic Optic Neuropathy

Related Publications

T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
November 2008, Investigative ophthalmology & visual science,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
August 2023, Life science alliance,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
January 2020, Marine drugs,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
June 2023, International immunopharmacology,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
April 2024, Molecular therapy : the journal of the American Society of Gene Therapy,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
February 2020, Investigative ophthalmology & visual science,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
August 2021, Investigative ophthalmology & visual science,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
February 1975, Investigative ophthalmology,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
September 2017, Investigative ophthalmology & visual science,
T Jehle, and W Meschede, and R Dersch, and N Feltgen, and M Bach, and W A Lagrèze
February 2008, Cellular and molecular neurobiology,
Copied contents to your clipboard!